Skip to main content
. Author manuscript; available in PMC: 2015 Apr 15.
Published in final edited form as: Free Radic Biol Med. 2010 Jul 13;49(6):1119–1128. doi: 10.1016/j.freeradbiomed.2010.06.030

Fig. 7.

Fig. 7

AP-ICAM peptide increases PI3 kinase activity, which modulates intracellular GSH production and GCL activity. (A) GSH levels after cellular treatment with AP-ICAM peptide plus either wortmannin (6 µM) or LY 294002 (20 µM) (normalized to AP-ICAM treatment alone). (B) GCL activity after cellular treatment with the AP-ICAM peptide plus wortmannin (6 µM) or LY 294002 (20 µM) (normalized to AP-ICAM treatment alone). (C) Changes in DCF fluorescence between AP-ICAM and AP-ICAM plus wortmannin (6 µM) or LY 294002 (20 µM). (D) Changes in PI3K activity after AP-ICAM treatment with or without PEG–SOD or PEG–catalase at various time points. n=5, #p<0.001 versus AP-ICAM alone, *p<0.01 versus AP peptide or time 0 min, experiments performed in triplicate.